BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 37415371)

  • 1. Assessment of Knowledge and Perception of Sodium-Glucose Co-transporter 2 (SGLT-2) Inhibitors Prescription among Physicians in Saudi Arabia.
    Somaili M; Oraibia O; Darraj M; Hassan A; Moafa E; Kulaybi A; Shubayli S; Moafa R; Mghfori G; Jaafari A; Somily M
    Curr Diabetes Rev; 2024; 20(4):e060723218471. PubMed ID: 37415371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal assessment of the quality of life and patterns of antidiabetic medication use in patients with type 2 diabetes, Saudi Arabia perspective, DISCOVER study.
    Al-Rubeaan K; Banah F; Alruwaily FG; Sheshah E; Alnaqeb D; AlQahtani AM; Ewais D; Al Juhani N; Hassan AH; Youssef AM
    Curr Med Res Opin; 2023 Jan; 39(1):27-35. PubMed ID: 36342972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prescribing sodium-glucose co-transporter-2 inhibitors for type 2 diabetes in primary care: influence of renal function and heart failure diagnosis.
    Hinton W; Feher MD; Munro N; Joy M; de Lusignan S
    Cardiovasc Diabetol; 2021 Jun; 20(1):130. PubMed ID: 34183018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Knowledge, attitudes, and practices regarding diabetic retinopathy among primary health care physicians in Al-Hasa, Saudi Arabia.
    Alhejji AE; Alsultan MA; Alshareet MA; Alkhamis FA; Aljaafary MA; Alshaqaqiq AI; Nabouli MR; Ibrahim Ali S
    J Prev Med Hyg; 2020 Mar; 61(1):E85-E91. PubMed ID: 32490273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium-glucose co-transporter-2 inhibitors, the latest residents on the block: Impact on glycaemic control at a general practice level in England.
    Heald AH; Fryer AA; Anderson SG; Livingston M; Lunt M; Davies M; Moreno GYC; Gadsby R; Young RJ; Stedman M
    Diabetes Obes Metab; 2018 Jul; 20(7):1659-1669. PubMed ID: 29516618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physician's knowledge and opinions on human papillomavirus vaccination: a cross-sectional study, Saudi Arabia.
    Anfinan NM
    BMC Health Serv Res; 2019 Dec; 19(1):963. PubMed ID: 31830983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Cross-Sectional Study about Knowledge, Attitude, and Practices among Primary Health Care Physicians in Jazan Province, Saudi Arabia, Regarding Rome IV Criteria for Diagnosis of Irritable Bowel Syndrome.
    Abusageah F; Hakami A; Zogel B; Zaalah S; Alfaifi S; Shubayli S; Hakami K; Qadah E; Aldharman S; Hakami F; Alqasemi M; Mobarki M; Alhazmi AH
    Medicina (Kaunas); 2022 Dec; 58(12):. PubMed ID: 36557013
    [No Abstract]   [Full Text] [Related]  

  • 8. Baseline Characteristics Associated With Sodium-Glucose Cotransporter Inhibitor Prescriptions in Type 2 Diabetic Patients in Jazan, Saudi Arabia.
    Somaili M; Oraibi O; Mohrag M; Hommadi A; Moafa E; Kulaybi A; Shobayli S; Moafa R; Mhgfory G; Jaafari A; Shami A; Majrashi K
    Cureus; 2022 Apr; 14(4):e24284. PubMed ID: 35602773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Race and Ethnicity With Prescription of SGLT2 Inhibitors and GLP1 Receptor Agonists Among Patients With Type 2 Diabetes in the Veterans Health Administration System.
    Lamprea-Montealegre JA; Madden E; Tummalapalli SL; Peralta C; Neilands TB; Garcia PK; Muiru A; Karliner L; Shlipak MG; Estrella MM
    JAMA; 2022 Sep; 328(9):861-871. PubMed ID: 36066519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolving physicians' perceptions and practices regarding use of SGLT2 inhibitors for type 2 diabetes during Ramadan fasting.
    Beshyah SA; Hafidh K; Shaikh TG
    Diabetes Res Clin Pract; 2020 Oct; 168():108389. PubMed ID: 32858101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Self-identified prescriber tendencies in sodium-glucose cotransporter-2 inhibitor outpatient prescribing.
    Thompson K; Bowers BL; Evans AM
    J Am Pharm Assoc (2003); 2024; 64(3):102068. PubMed ID: 38492740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adoption of New Glucose-Lowering Medications in the U.S.-The Case of SGLT2 Inhibitors: Nationwide Cohort Study.
    McCoy RG; Dykhoff HJ; Sangaralingham L; Ross JS; Karaca-Mandic P; Montori VM; Shah ND
    Diabetes Technol Ther; 2019 Dec; 21(12):702-712. PubMed ID: 31418588
    [No Abstract]   [Full Text] [Related]  

  • 13. Prescribing Trends of the Sodium-Glucose Cotransporter-2 Inhibitors Among Different Physician Specialties in Canada (2015-2021).
    Alkabbani W; Gamble JM
    Can J Diabetes; 2023 Mar; 47(2):153-161. PubMed ID: 36481264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
    Handelsman Y
    Adv Ther; 2019 Oct; 36(10):2567-2586. PubMed ID: 31444707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physicians' and nurses' perceptions and attitudes toward sickle cell disease patients in Jazan, Saudi Arabia.
    Hazzazi AA; Ageeli MH; Sharahili KA; Hamaly HM; Aqeeli MH; Altherwi TI; Bakkar M; Malhan H
    Saudi Med J; 2020 Aug; 41(8):841-848. PubMed ID: 32789425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atherosclerotic disease and risk factor modification in Saudi Arabia: a call to action.
    Al-Omran M
    Vasc Health Risk Manag; 2012; 8():349-55. PubMed ID: 22701328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Awareness, practices, and barriers regarding smoking cessation treatment among physicians in Saudi Arabia.
    Jradi H
    J Addict Dis; 2017; 36(1):53-59. PubMed ID: 26566876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prescribing Patterns of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with CKD: A Cross-Sectional Registry Analysis.
    Zhuo M; Li J; Buckley LF; Tummalapalli SL; Mount DB; Steele DJR; Lucier DJ; Mendu ML
    Kidney360; 2022 Mar; 3(3):455-464. PubMed ID: 35582176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiology-Led Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodium-Glucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or Add-on to Metformin Monotherapy) in Type 2 Diabetes in Scotland.
    Caparrotta TM; Blackbourn LAK; McGurnaghan SJ; Chalmers J; Lindsay R; McCrimmon R; McKnight J; Wild S; Petrie JR; Philip S; McKeigue PM; Webb DJ; Sattar N; Colhoun HM;
    Diabetes Care; 2020 Sep; 43(9):2034-2041. PubMed ID: 32581068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Knowledge and Attitude Toward Organ Donation Among the Adult Population in Jazan, Saudi Arabia.
    Somaili M; Masmali A; Haqawi I; Al-Hulaibi M; AlHabji AA; Salami A; Ageel AA; Sultan Y; Alhazemi A; Moharg F; Almansour O; Ahmed AE
    Cureus; 2022 Jul; 14(7):e27002. PubMed ID: 35989830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.